This dissertation is accessible only to the Illinois State University community.
- Off-Campus ISU Users: To download this item, click the "Off-Campus Download" button below. You will be prompted to log in with your ISU ULID and password.
- Non-ISU Users: Contact your library to request this item through interlibrary loan.
Date of Award
Thesis-ISU Access Only
Master of Science (MS)
Department of Chemistry
The Human T cell leukemia virus (HTLV-1) has been established as the first retrovirus to be directly associated with human malignancy. A commonality between HTLV-1 and other retroviruses is that it encodes a protease (PR) necessary for it to mature. Building upon the synthetic model of the known protease of HTLV-1 established by Aimoto and co-workers, Kenichi Akaji and co-workers were able to synthesize a protease inhibitor that successfully interacted with the protease. We became interested in the asymmetric synthesis of the Akaji protease inhibitor for the HTLV-1 using an oxazolidine-2-thione directed asymmetric glycolate aldol addition route in other to have a shorter and efficient synthesis. Once this process was successfully completed, we proceeded to reductively cleave the chiral auxiliary to generate the corresponding diol that was chemoselectively sulfonylated with p-toluenesulfonyl chloride. Treatment of this system with a variety of nucleophiles resulted in oxetane derivative formation. After numerous attempts to open the oxetane derivative minor product, an alternate pathway of transamidation was pursued.
Addo, Marian Aba, "Efforts towards the Formal Synthesis of the Akaji Human T-cell Leukemia Virus Type 1 ( Htlv-1 ) Protease Inhibitor via an Asymmetric Glycolate Aldol Addition Route" (2020). Theses and Dissertations. 1273.